Shattuck Labs Stock Rises Nearly 5% on Analyst Upgrade
On July 24, 2026, Shattuck Labs (STTK) saw its stock rise nearly 5%, closing at $7.43 per share after an analyst upgrade from J.P. Morgan's Brian Cheng. The analyst assigned the company a 'buy' rating with a price target of $10 per share — representing potential upside of about 35% over current levels. Cheng cited positive early data for Shattuck’s lead drug candidate, SL-325, which is being developed to treat inflammatory bowel disease. The compound showed favorable safety and engagement in trials with healthy volunteers, suggesting strong development potential if it progresses successfully through regulatory approval processes. The drug is set to enter Phase 2 clinical testing later this year. The biotech sector often experiences volatility based on early-stage trial data or analyst sentiment shifts. Shattuck’s stock rally reflects investor optimism about the company's pipeline and its ability to advance SL-325, though it remains a high-risk investment due to the typical uncertainties of drug development.
Tickers: $JPM
Topics: analyst upgrade biotech clinical trials